Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.38 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22054572 | 1.00 | SMN1; SMN2 (0.45) | SMN1; SMN2SIGMAR1EPHX1KISS1REPHX2 | |
| SCHEMBL22054640 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2EPHX1EPHX2HDAC4HDAC1 | |
| SCHEMBL20792784 | 0.88 | SMN1; SMN2 (0.45) | SMN1; SMN2EPHX1EPHX2HDAC4HDAC1 | |
| SCHEMBL22053731 | 0.85 | SMN1; SMN2 (0.43) | SMN1; SMN2EPHX1EPHX2HDAC4HDAC1 | |
| SCHEMBL17453157 | 0.83 | CPB2 (0.47) | SMN1; SMN2 | |
| SCHEMBL22054642 | 0.83 | CPB2 (0.47) | SMN1; SMN2 | |
| SCHEMBL24860120 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2EPHX1EPHX2HDAC4HDAC1 | |
| SCHEMBL20801400 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2EPHX1EPHX2HDAC4HDAC1 | |
| SCHEMBL22054574 | 0.81 | CPB2 (0.45) | SMN1; SMN2 | |
| SCHEMBL12766489 | 0.80 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165968-A1 | CANCER TREATMENT METHODS | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165968-A1 | CANCER TREATMENT METHODS | EGFR, ERBB2, FCGR2A | SMN1; SMN2 3723/4885SIGMAR1 2653/4885EPHX1 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.